• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

息肉状脉络膜血管病变光动力疗法的长期结果

Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.

作者信息

Akaza Eriko, Mori Ryusaburo, Yuzawa Mitsuko

机构信息

Department of Ophthalmology, School of Medicine, Nihon University, Japan.

出版信息

Retina. 2008 May;28(5):717-22. doi: 10.1097/IAE.0b013e31816577cb.

DOI:10.1097/IAE.0b013e31816577cb
PMID:18463515
Abstract

PURPOSE

This study evaluated the results of photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) 24 months or more after treatment.

METHODS

The study involved 47 eyes of 47 patients with PCV followed for 24 months or more after the first PDT. Fundus appearance, indocyanine green angiographic findings, and visual acuity (VA) were compared before PDT, and then at 3 months, 12 months, and the final visit after the first PDT.

RESULTS

At the final visit, VA was preserved or improved in 37 (79%) of the 47 eyes. Recurrence of polypoidal lesions was noted in 30 eyes (64%). An abnormal branching vascular network persisted in all subjects. In 26 of the 30 eyes exhibited recurrence of polypoidal lesions, which appeared in the periphery of the expanded abnormal branching vascular network.

CONCLUSION

Patients with PCV need to be followed for long periods of time after PDT because of the high incidence of polypoidal lesion recurrence. However, since polypoidal lesions often recur outside the fovea, and thus have little effect on VA, PDT can be expected to exert long-term efficacy in treating PCV.

摘要

目的

本研究评估了光动力疗法(PDT)治疗息肉样脉络膜血管病变(PCV)24个月及更长时间后的效果。

方法

该研究纳入了47例PCV患者的47只眼,在首次PDT后随访24个月及更长时间。比较了PDT前、首次PDT后3个月、12个月及最后一次随访时的眼底外观、吲哚菁绿血管造影结果和视力(VA)。

结果

在最后一次随访时,47只眼中有37只(79%)的视力得以保留或提高。30只眼(64%)出现了息肉样病变复发。所有受试者均存在异常分支血管网。在30只出现息肉样病变复发的眼中,有26只出现在扩张的异常分支血管网周边。

结论

由于息肉样病变复发率高,PCV患者在PDT后需要长期随访。然而,由于息肉样病变常发生在黄斑中心凹以外,因此对视力影响较小,预计PDT在治疗PCV方面可发挥长期疗效。

相似文献

1
Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.息肉状脉络膜血管病变光动力疗法的长期结果
Retina. 2008 May;28(5):717-22. doi: 10.1097/IAE.0b013e31816577cb.
2
Role of photodynamic therapy in polypoidal choroidal vasculopathy.光动力疗法在息肉样脉络膜血管病变中的作用。
Jpn J Ophthalmol. 2007 Jul-Aug;51(4):270-7. doi: 10.1007/s10384-007-0452-3. Epub 2007 Aug 3.
3
Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy.光动力治疗后息肉状脉络膜血管病变的显著血管变化。
Br J Ophthalmol. 2008 Jul;92(7):936-40. doi: 10.1136/bjo.2007.132357.
4
Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy.吲哚菁绿血管造影:息肉状脉络膜血管病变的光动力治疗引导
Am J Ophthalmol. 2007 Jul;144(1):7-14. doi: 10.1016/j.ajo.2007.03.014. Epub 2007 Apr 30.
5
Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.抗血管内皮生长因子药物联合光动力疗法治疗息肉状脉络膜血管病变的长期疗效和安全性。
Indian J Ophthalmol. 2018 Aug;66(8):1119-1127. doi: 10.4103/ijo.IJO_1222_17.
6
Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.光动力疗法联合玻璃体内注射雷珠单抗治疗息肉状脉络膜血管病变。
Am J Ophthalmol. 2012 Jan;153(1):68-80.e1. doi: 10.1016/j.ajo.2011.07.001. Epub 2011 Sep 9.
7
One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.减少强度的光动力疗法治疗息肉样脉络膜血管病变的一年疗效。
Am J Ophthalmol. 2010 Mar;149(3):465-71.e1. doi: 10.1016/j.ajo.2009.09.020. Epub 2009 Dec 30.
8
Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up.光动力疗法联合维替泊芬治疗息肉样脉络膜血管病变:3 年随访结果。
Retina. 2010 Sep;30(8):1197-205. doi: 10.1097/IAE.0b013e3181d37486.
9
One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.日本患者年龄相关性黄斑变性和息肉样脉络膜血管病变的光动力疗法一年期疗效
Ophthalmology. 2008 Jan;115(1):141-6. doi: 10.1016/j.ophtha.2007.02.031. Epub 2007 Jun 20.
10
Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy.眼内雷珠单抗联合维替泊芬光动力疗法治疗息肉状脉络膜血管病变。
Retina. 2011 Jul-Aug;31(7):1287-93. doi: 10.1097/IAE.0b013e3182003ccd.

引用本文的文献

1
Comparative efficacy of photodynamic therapy (PDT), ranibizumab, aflibercept monotherapy, and combination therapies for polypoidal choroidal vasculopathy: a network meta-analysis of randomized controlled trials.光动力疗法(PDT)、雷珠单抗、阿柏西普单药治疗以及联合治疗对息肉状脉络膜血管病变的比较疗效:一项随机对照试验的网状Meta分析
BMC Ophthalmol. 2025 Jul 31;25(1):440. doi: 10.1186/s12886-025-04249-8.
2
The Past, Present, and Future Perspective of Photodynamic Therapy for Age-Related Macular Degeneration.光动力疗法治疗年龄相关性黄斑变性的过去、现在和未来展望
J Clin Med. 2025 Feb 13;14(4):1240. doi: 10.3390/jcm14041240.
3
Red Light-Triggered Anti-Angiogenic and Photodynamic Combination Therapy of Age-Related Macular Degeneration.
基于红光触发的抗血管生成和光动力联合疗法治疗年龄相关性黄斑变性。
Adv Sci (Weinh). 2023 Nov;10(31):e2301985. doi: 10.1002/advs.202301985. Epub 2023 Sep 14.
4
Quantitative analysis of branching neovascular networks in polypoidal choroidal vasculopathy by optical coherence tomography angiography after photodynamic therapy and anti-vascular endothelial growth factor combination therapy.光动力疗法联合抗血管内皮生长因子治疗后多灶性脉络膜血管病变的光学相干断层扫描血管造影分支新生血管网络的定量分析。
Graefes Arch Clin Exp Ophthalmol. 2022 Jul;260(7):2249-2260. doi: 10.1007/s00417-022-05583-z. Epub 2022 Feb 8.
5
Recurrence and visual prognostic factors of polypoidal choroidal vasculopathy: 5-year results.息肉样脉络膜血管病变的复发和视觉预后因素:5 年结果。
Sci Rep. 2021 Nov 3;11(1):21572. doi: 10.1038/s41598-021-00904-4.
6
Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy.雷珠单抗对息肉状脉络膜血管病变患者的治疗效果。
BMC Ophthalmol. 2019 Jul 19;19(1):153. doi: 10.1186/s12886-019-1156-4.
7
Polypoidal choroidal vasculopathy: An update on current management and review of literature.息肉样脉络膜血管病变:当前治疗进展及文献综述
Taiwan J Ophthalmol. 2019 Apr-Jun;9(2):72-92. doi: 10.4103/tjo.tjo_35_18.
8
One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy.眼内注射阿柏西普联合光动力疗法治疗息肉状脉络膜血管病变的一年疗效。
BMC Pharmacol Toxicol. 2019 May 14;20(1):29. doi: 10.1186/s40360-019-0310-1.
9
Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports.雷珠单抗联合光动力疗法使息肉样脉络膜血管病变分支状血管网完全消退:两例病例报告
BMC Ophthalmol. 2018 Nov 3;18(1):284. doi: 10.1186/s12886-018-0952-6.
10
Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.抗血管内皮生长因子药物联合光动力疗法治疗息肉状脉络膜血管病变的长期疗效和安全性。
Indian J Ophthalmol. 2018 Aug;66(8):1119-1127. doi: 10.4103/ijo.IJO_1222_17.